Skip to main content

Table 2 Clinical and parasitological response by treatment group

From: Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali

  ETF LCF LPF ACPR*
CQ %(N) AQ %(N) SP %(N) CQ %(N) AQ %(N) SP %(N) CQ %(N) AQ %(N) SP %(N) CQ %(N) AQ %(N) SP %(N)
14 Days 2002 5.4 (5) 0.0 (0) 0.0 (0) 7.6 (7) 0.0 (0) 0.0 (0) 38.0 (35) 5.7 (3) 7.3 (4) 48.9 (45) 94.3 (50) 92.7 (51)
  2003 7.3 (8) 5.5 (3) 1.6 (1) 3.6 (4) 1.8 (1) 0.0 (0) 27.3 (30) 7.3 (4) 4.9 (3) 61.8 (68) 85.5 (47) 93.4 (57)
  Total 6.4 (13) 2.8 (3) 0.9 (1) 5.4 (11) 0.9 (1) 0.0 (0) 32.2 (65) 6.5 (7) 6.0 (7) 55.9 (113) 89.8 (97) 93.1 (108)
28 Days 2002 5.4 (5) 0.0 (0) 0.0 (0) 20.7 (19) 1.9 (1) 0.0 (0) 59.8 (55) 35.8 (19) 11.1 (6) 14.1 (13) 62.3 (33) 88.9 (48)
  2003 7.3 (8) 5.5 (3) 1.6 (1) 20.0 (22) 5.5 (3) 0.0 (0) 54.5 (60) 29.1 (16) 13.1 (8) 18.2 (20) 60.0 (33) 85.2 (52)
  Total 6.4 (13) 2.8 (3) 0.9 (1) 20.3 (41) 3.7 (4) 0.0 (0) 56.9 (115) 32.4 (35) 12.2 (14) 16.3 (33) 61.1 (66) 86.9 (100)
  1. *RCPA day 14: CQ vs. AQ, P < 0.001; CQ vs. SP, P < 0.001; AQ vs. SP, P = 0.3; RCPA day 28: CQ vs. AQ, P < 0.001; CQ vs. SP, P < 0.001; AQ vs. SP, P < 0.001